Fibrinogen is a 340 kDa plasma protein that circulates in blood at 2 - 4 g/L. It is composed by two set of polypeptide chains: Aα, Bβ, and γ. Fibrinogen plays diverse roles in coagulation and inflammation. Thrombin is formed after sequential steps of proteases activation, cleaving fibrinogen at the N-terminal of Aα and Bβ chains. This partially degraded fibrinogen starts to polymerize forming at the end a tridimensional meshwork, the fibrin clot that is further stabilized by the transglutaminase FXIIIa (reviewed in ). The fibrin clot together with aggregated platelets form a plug that halt blood extravasation, and simultaneously became a temporal extracellular matrix for wound healing  and angiogenesis . Fibrin(ogen) achieve these physiologic functions through its binding to several receptors, integrin and no integrin type, present in platelets (αIIb-β3), endothelial cells (αvβ3, ICAM-1, and VE-cadherin), and leucocytes (αMβ2 and αxβ2).
Integrins are one of the major families of cell adhesion receptors composed by an α and β subunit, non-covalently linked . Both subunits are type I transmembrane proteins, containing large extracellular domains and, in general, a short cytoplasmic domains. Integrin affinities for their extracellular ligands, such as fibronectin, fibrinogen and collagen are regulated by cellular signaling that results in “inside-out” integrin activation. The αIIb-β3 and αvβ3 recognize ligands containing an RGD sequence . Immobilized fibrinogen binds to the platelet receptor αIIb-β3 through the sequence γ 400-411 (HHLGGAKQ
Fibrin(ogen) bridge inflammatory cells to endothelium promoting migration and inflammation by interacting with the leukocyte receptor αMβ2 and endothelial cell receptor ICAM-1 [11, 12]. Fibrin may also bridge leukocytes to the endothelium through the interaction with the endothelial cell receptor VE-cadherin . The fibrin binding to the non integrin receptor VE-cadherin take place at the N-terminal part of fibrin (β15-42)2 sequences [14, 15] that become exposed after fibrinopeptides B released. Further, it was demonstrated that fibrin promotes the formation of capillaries after binding to VE-cadherin .
Several studies have shown that near the endothelial cells surface the fibrin clot is organized into a dense structure, while farther from the cell´s surface, at approximately 30 to 50 μm the fibrin fibers are looser [17, 18]. This fibers arrangement proximal to the cells is lost in the presence of antibodies against αv and/or β3 integrin subunits  or the synthetic RGD peptide . In contrast, other studies have concluded that the fibrin structure near the cell surface was related to the thrombin generated on the cells surface, and in their experiments the addition of RGD peptide did not affect the fibrin structure [19, 20]. They did not add antibodies against the integrin subunits that would be more conclusive.
Dysfibrinogenemias are inherited fibrinogen disorders that affect fibrin(ogen) functions according to the localization of the mutation. The affected patients are diagnosed due to a prolonged thrombin time, decreased functional fibrinogen and normal antigenic levels .
Abnormal fibrinogens with mutations located in the integrin/non integrin binding sites have been reported. Fibrinogen Kaiserslautern (γ Lys380Asn) and Osaka V (γ Arg375GLy) had delayed clot retraction and impaired αIIb-β3 binding [22, 23]. Fibrinogen Nieuwegein, with a truncated Aα chain (stretch 454-610 deleted), was less supportive for endothelial cells invasion that was related to the abnormal clot structure rather than to the absence of the RGD integrin αvβ3 binding site (α 572-574).
In our laboratory we have examined the clot structure of several dysfibrinogenemias near the cell surface of human dermal microvascular endothelial cells (HMEC-1), forming clots with plasma and purified fibrinogen. We have included fibrinogen Caracas I (Aα 466-610 deleted) and fibrinogen Caracas V (Aα Ser532Cys), with mutations in or near α 572-574, and fibrinogen Caracas VIII (Bβ Tyr41Asn), all of them heterozygous for the mutation. Furthermore, for comparative purposes, clots were formed with fragment X, a degraded form of fibrinogen with around 10% of αC domain remaining, and partially degraded Bβ chain (1-42 residues) .
2. Materials and methods
2.1. Fibrinogen coupling to Alexa Fluor® 488
Human plasma fibrinogen was purified in the laboratory by standard protocol . The fibrinogen was coupled to Alexa Fluor 488® (Invitrogen, Molecular Probes, Rochester, NY, USA) according to manufacturer guidelines. Briefly, purified protein was diluted to 2 mg/ml with phosphate buffered saline (PBS), and 1M sodium bicarbonate solution was added (1:10). This mixture was transferred to the dye vial, gently mixed and stirred during 1 h at room temperature. The coupled fibrinogen to Alexa 488 was separated from the uncoupled dye using a column provided by the manufacturer. The absorbance of the conjugate solution was read at 280 and 494 nm and protein concentration was calculated using the following equation:
Protein concentration (mg/ml) = [A280 – (A494 x 0.11) x dilution factor]/1.51
2.2. Cell culture and clot assembly
The human dermal microvascular endothelial cells (HMEC-1) were kindly donated by Dr. Edwin Ades and Mr. Francisco J. Candal of the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA), and Dr. Thomas Lawley of Emory University (Atlanta, GA, USA). HMEC-1 were cultured in MCDB 131 medium supplemented with 10 % fetal bovine serum, epidermal growth factor (10 ng/ml), penicillin (100 U/ml), streptomycin (100 μg/ml), fungizone 0.25 μg/ml and 2 mM L-glutamine. Cells (120,000) were seeded in Lab Tek glass chamber slides and maintained at 37 °C in a humid atmosphere with 95 % air and 5 % CO2 up to reach approximately 80 % confluence. The cells were stained with 4 μM di-8-anepps (Invitrogen, Molecular Probes, Rochester, NY, USA) for 15 min and washed three times with PBS. Apart, 200 μl of plasma (2 mg/ml fibrinogen concentration) or purified fibrinogen (1 mg/ml) were mixed with fibrinogen - Alexa 488 (95 μg/ml), and clotted with a thrombin - CaCl2 solution, 2.7 and 1 nM of human thrombin (American Diagnostica, Greenwich, CT, USA), and 20 mM and 10 mM CaCl2, respectively. The mixture was immediately transferred on the top of the cells. Simultaneously, clots were formed in other wells in the absence of cells. Clot formation was allowed to progress for 2 h in a tissue culture incubator at 37 °C. Then, the top of the clot was loaded with 200 μl of MCDB 131 medium with not supplement.
2.3. Laser scanning confocal microscopy
The fibrin clots was observed in a laser scanning confocal microscopy (LSCM) system with 2 lasers, an argon ion laser (488 nm excitation and 515/530 LP filter for emission) and a HeNe laser (543 nm) mounted on one Nikon Eclipse TE 2000-U microscope. The objective used was Plan Apo VC 60X water immersion with a work distance of 0.27. The acquisition pinhole was set to 60 μm. The confocal was controlled through the software EZ-C1 from Nikon. The images were acquired with a field of view of 212x212 µm. A z- and orthogonal 3D projection of 10 μm thick (0.5 µm/slice) were done near the cell surface, far from the cell surface (20 to 30 μm), and without cells, using ImageJ 1.46 and Olympus FV10ASW (version 0.2010404) softwares, respectively. For images analysis, the thickness chosen was 10 μm near the cell surface, 5 μm at 25 μm far from the cell surface, and 10 μm without cells. The histogram of the frequency
F: normalized fluorescence
F0: frequency of each gray-value
Fmin: frequency of the lowest gray value
Fmax: frequency the highest gray value
The mean of F was calculated (Fmean), and results represented as column graph, Fmean ± SEM. Statistical analysis was performed using the t-student, and
3. Results and discussion
Fibrin clots anchor to different receptors of different cell types through specific fibrin recognition sites present in the three fibrinogen chains. The clot structure changes according to the distance to the cell surface. Near the cell the fibrin density is increased, and pores filling space are smaller compared to greater distance, at approximately 30 μm. This particular fibrin architecture is related to the presence of cells since when clots were formed in its absence the clot structure was uniform, resembling that observed far from the cell surface. The figure 1 shows the column graph of the Fmean for Alexa 488 of clots performed with plasma, and figure 2 for clots done with purified fibrinogen. For patients and controls, the fluorescence intensity was greater near the cell surface compared to that far from it, and without the presence of cells, which were statistically significant at
The figure 3 shows a Z projection of the region close to the cell surface, 10 μm thick, when clots were formed with plasma (figure 3a), with purified fibrinogen (figure 3b), and with fibrinogen fragment X (figure 3c). The fields where fibers interacted with cell receptors are brighter compared to that without interactions. Clots formed with plasma and purified fibrinogen had 1.3 and 1.6 times more interaction with the cell surface compared to fragment X, differences statistically significant. It was common to observe stressed fibers as consequence of fibrin binding to cell receptors (signaled with arrow in figure 3b). The interaction of purified fibrinogen with cells was approximately 1.2 times higher than plasma (p<0.05). Although plasma had more fibrinogen (0.4 mg total) compared to purified fibrinogen (0.2 mg), the presence of other proteins that compete with fibrin for receptor binding, mainly fibronectin and vitronectin, could decrease fibrin interaction.
When Z projections were done farther from the cell surface (from 20 to 30 μm), figure 4, the fibrin structure became more homogeneous, the fibrin density decreased and the pores filling space were larger both in plasma (figure 4a) and purified fibrinogen clots (figure 4b), similar to what was observed when clots were formed without cells (figure 4d and 4e); however, the appearance of the fragment X - fibrin almost did not change (figure 4c), similar to the condition without cells (compare figure 3c with 4c and 4f).
Our results confirmed previous work performed by Jerome et al . Other authors have found that the clot organization was related to the thrombin generated on the cell surface, and when they added exogenous thrombin no change was observed in the fibrin morphology .
In order to study the effect of certain fibrinogen mutations on fibrin organization on the cell surface, we have chosen dysfibrinogenemias with mutations in or close to the αVβ3 integrin binding site (α572-574): fibrinogen Caracas I (Aα Ser466Stop) and Caracas V (Aα Ser532Cys); and in the VE-Cadherin binding site (Bβ15-66)2 : fibrinogen Caracas VIII (Bβ Tyr41Asn).
Fibrinogen Caracas I and V formed tight clots composed by very thin fibers (figure 5 and 6). The figure 2 shows that fibrin Caracas I and V have less interaction with the receptors of HMEC-1 compared to control (1.3 and 1.5, respectively). The fibrin architecture near the cell surface is shown in figure 5a (Caracas I) and 5b (Caracas V). This pattern was lost far from the cell surface, similar to that without cells (figure 6a and 6b, and 6d and 6e, respectively). Both fibrinogen Caracas I and V have decreased interaction to the αvβ3 receptor, due to that fibrinogen Caracas I has decreased population of fibrinogen molecules with α572-574, while the point mutation of Caracas V at α Ser532 probably is closer to the integrin binding site.
The clinical implications of these results are far to be understood, while fibrinogen Caracas I outcome was mild bleeder, fibrinogen Caracas V was thrombotic. It is more likely that less interaction of the thrombus with the endothelium would embolize the vessel blood, since less adhesion could imply that the force needed to sweep it away are less. Fibrinogen Caracas V had pulmonary embolism but not Caracas I. If there is a threshold value, since fibrinogen Caracas V had less interaction, is subject of future investigation.
The fibrin network of fibrinogen Caracas VIII was done with plasma. The meshwork was composed by thick fibers and large pores (figure 5 and 6). The interaction of patient´s fibers with the cell receptors was approximately 1.2 times less than control plasma (figure 1); in spite the fact that the C-terminal region of the α-chain was normal. The figure 5c shows fibrin Caracas VIII organization on the cell surface, compared to fibrinogen Caracas I and V, the fibrin density around the cells was very decreased. The architecture of Caracas VIII fibrin far from the cell surface was similar to that performed without cells (figure 6c and 6f, respectively).
One possible explanation is that fiber thickness influence the quantity of ligands per unit of fibrin surface. This would partially explain why Fibrinogen Caracas VIII with normal αC had less interaction with the cells. The contribution of fibrin binding to VE-cadherin to fibrin organization is less clear, since the VE-cadherin contributes to cell-cell and not to cell-extracellular matrix interaction .
Fibrinogen Caracas VIII was asymptomatic, and the fibrinolysis process was much faster compared to the above mentioned fibrinogens. Probably this abnormal fibrinogen is protected against embolization due to the fast lysis rate.
The fibrin formed with fibrinogen fragment X had approximately 90% less αC domains and degraded N-terminal Bβ chain, and the least interaction with the cell surface, highlighting the importance of the α572-574 for fibrin organization on the cell surface.
In summary, these preliminary data indicated that the fibrin structure is important for its interaction with cell receptors and that the α572-574 stretch seemed to be the main responsible of fibrin organization on cell surface.
AcknowledgmentsWe are grateful to Dr. Edwin Ades and Mr. Francisco J. Candal of the Centers for Disease Control and Prevention, and Dr. Thomas Lawley of Emory University (Atlanta, GA, USA) for the donation of the human microvascular endothelial cells (HMEC-1). We want to thank M.Sc. Jenny Dimelza Gómez from the University of Pamplona of Colombia for the fragment X preparation.
ed. Fibrinogen and Fibrin: structure and functional aspects., ed. R. Marchi. Stief T. W 2012NOVA.
Fibrin structure and wound healing. Journal of thrombosis and haemostasis, Laurens N and P Koolwijk M. P De Maat 2006 932 939
Role of fibrin matrix in angiogenesis. Annals of the New York Academy of Sciences, Van Hinsbergh V. W and A Collen P Koolwijk 2001 426 437
Integrins: bidirectional, allosteric signaling machines. Cell, Hynes R. O 2002 673 687
Integrin ligands at a glance. Journal of cell science, Humphries J. D and A Byron M. J Humphries 2006Pt 19): 3901 3903
Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry, Kloczewiak M et al 1984 1767 1774
Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell, Cheresh D. A et al 1989 945 953
Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. The Journal of biological chemistry, Smith J. W et al 1990 12267 12271
Identification of a novel binding site for platelet integrins alpha IIb beta 3 (GPIIbIIIa) and alpha 5 beta 1 in the gamma C-domain of fibrinogen. The Journal of biological chemistry, Podolnikova N. P et al 2003 32251 32258
Evidence for new endothelial cell binding sites on fibrinogen. Thrombosis and haemostasis, Smith R. A et al 2000 819 825
Regulation of leukocyte-endothelium interaction by fibrinogen. Thrombosis and haemostasis, Altieri D. C 1999 781 786
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell, Languino L. R et al 1993 1423 1434
The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nature Medicine, Petzelbauer P et al 2005 298 304
Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. The Journal of biological chemistry, Bach T. L et al 1998 30719 30728
Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. Biochemistry, and Gorlatov S L Medved 2002 4107 4116
Interaction of fibrin with VE-cadherin. Annals of the New York Academy of Sciences, Martinez J et al 2001 386 405
Endothelial cells organize fibrin clots into structures that are more resistant to lysis. Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada, Jerome W. G and S Handt R. R Hantgan 2005 268 277
Structure of fibrin network of two abnormal fibrinogens with mutations in the alphaC domain on the human dermal microvascular endothelial cells 1. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, Marchi R et al 2011 706 711
Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arteriosclerosis, thrombosis, and vascular biology, Campbell R. A et al 2008 2247 2254
Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood, Campbell R. A et al 2009 4886 4896
Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias. Haemophilia : the official journal of the World Federation of Hemophilia, and Hill M G Dolan 2008 889 897
Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. British journal of haematology, Ridgway H. J et al 1997 562 569
Characterization of an abnormal fibrinogen Osaka V with the replacement of gamma-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis. The Journal of biological chemistry, Yoshida N et al 1992 2753 2759
The structure of the fibrinogen degradation products. Progress in hemostasis and thrombosis, and Marder V. J A. Z Budzynski 1974 141 174
K.P., A modified beta-alanine precipitation procedure to prepare fibrinogen free of antithrombin III and plasminogen. Thrombosis research, Jacobsen E 1973 145 148
Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: localization of the fibrin-binding site within the third extracellular VE-cadherin domain. Biochemistry, and Yakovlev S L Medved 2009 5171 5179
The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One, Alghisi G. C and L Ponsonnet C Ruegg 2009 e4449